Dr. Khan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2799 West Grand Boulevard
Detroit, MI 48208Phone+1 313-916-1841
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2005 - 2008- University of MichiganResidency, Internal Medicine, 1999 - 2002
Kilpauk Medical CollegeClass of 1998
Certifications & Licensure
MI State Medical License 2004 - 2026
OH State Medical License 2001 - 2002- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Futibatinib in Patients With Specific FGFR Aberrations Start of enrollment: 2020 Aug 24
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Start of enrollment: 2023 Jul 13
Roles: Principal Investigator
Publications & Presentations
PubMed
- Treatment of unresectable and resectable stage IV colorectal cancer.Julia L Bachler, Gazala N Khan, Ira S Wollner, Philip A Philip
Clinical Advances in Hematology & Oncology. 2024-11-01 - 2 citationsLong-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer.Aseem Rai Bhatnagar, Farzan Siddiqui, Gazala Khan, Robert Pompa, David Kwon
Biomedicines. 2024-05-11 - MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon.Jitender Monga, Ritisha Ghosh, Rohith Guddeti, Dhananjay Chitale, Gazala Khan
Frontiers in Oncology. 2024-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
